Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail
-

FDA Drug Safety Newsletter - Volume 1, Number 4, Summer 2008

This publication provides postmarketing information to healthcare professionals to enhance communication of new drug safety information, raise awareness of reported adverse events, and stimulate additional adverse event reporting.
    

In This Issue
 

Editor's Note

Postmarketing Reviews

Reports of pneumonitis associated with the use of mefloquine (marketed as LARIAM and generics)

Reports of serious skin reactions associated with the use of lenalidomide (marketed as REVLIMID)

Reports of rhabdomyolysis associated with the concomitant use of amiodarone (marketed as CORDARONE and PACERONE) and simvastatin (marketed as ZOCOR and generics) or simvastatin-combination products (marketed as VYTORIN and SIMCOR)

Reports of iatrogenic, sometimes fatal, hypoglycemia in association with icodextrin (EXTRANEAL) and certain point-of-care blood glucose monitors utilizing glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase (GDO) reagents

Feature Article

A review of the challenges and efforts to reduce medication errors

Drug Safety Communications

List of advisories on drug safety posted on FDA's Web site from May 1, 2008 through August 31, 2008, with related links
physician, x-ray, pill box

U.S. Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
5600 Fishers Lane, Rockville MD 20857-0001
Phone: 1-888-INFO-FDA (1-888-463-6332)

Renan A. Bonnel, PharmD, MPH
Senior Scientific Editor

Gregory D. Busse, PhD
Editor

Acknowledgments:
Office of Surveillance and Epidemiology and Office of New Drugs

Contributing Authors:
S. Christopher Jones, PharmD, MS (mefloquine hydrochloride)
Gregory D. Busse, PhD (medication errors)

Art Direction and Design: Michael Ermarth

We value your comments. Please let us know by reaching us at Comments. All text in the Drug Safety Newsletter is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

 

Page created: September 18, 2008
-
-